These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32019703)

  • 41. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.
    Thompson A; Gurtman A; Patterson S; Juergens C; Laudat F; Emini EA; Gruber WC; Scott DA
    Vaccine; 2013 Oct; 31(45):5289-95. PubMed ID: 23973321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
    Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
    Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
    Amdekar YK; Lalwani SK; Bavdekar A; Balasubramanian S; Chhatwal J; Bhat SR; Verghese VP; Tansey SP; Gadgil D; Jiang Q; Pride M; Emini EA; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2013 May; 32(5):509-16. PubMed ID: 23190777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
    Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
    Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
    Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
    Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
    PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Pandemic and Nonpandemic Influenza Periods.
    Hernández S; Muñoz-Almagro C; Ciruela P; Soldevila N; Izquierdo C; Codina MG; Díaz A; Moraga-Llop F; García-García JJ; Domínguez Á
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination.
    Van Buynder PG; Frosst G; Van Buynder JL; Tremblay FW; Ross A; Jardine C; Fei BG
    Influenza Other Respir Viruses; 2013 Mar; 7(2):184-90. PubMed ID: 22498052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.
    Sun Y; Christensen J; Hviid A; Li J; Vedsted P; Olsen J; Vestergaard M
    JAMA; 2012 Feb; 307(8):823-31. PubMed ID: 22357833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
    Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children.
    Walter EB; Hornik CP; Grohskopf L; McGee CE; Todd CA; Museru OI; Harrington L; Broder KR
    Vaccine; 2017 Dec; 35(48 Pt B):6664-6671. PubMed ID: 29056422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
    Zhu F; Hu Y; Li J; Ye Q; Young MM; Zhou X; Chen Z; Yan B; Liang JZ; Gruber WC; Giardina PC; Scott DA
    Pediatr Infect Dis J; 2016 Sep; 35(9):999-1010. PubMed ID: 27254028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.